Company: DMAC
Filing Date: 2025-08-12
Form Type: S-3
Source: 0001437749-25-026273
Chunk: 2

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: S-3
Chunk 2
---
 and sold from time to time under our sales agreement, dated August 12, 2025, with TD Securities (USA) LLC, as sales agent (Sales Agreement). |

The base prospectus immediately follows this explanatory note. The specific terms of any other securities to be offered pursuant to the base prospectus will be specified in one or more prospectus supplements to the base prospectus. The sales agreement prospectus supplement immediately follows the base prospectus. The common shares that may be offered, issued and sold by us under the sales agreement prospectus supplement are included in the $100,000,000 of securities that may be offered, issued and sold by us under the base prospectus. Upon termination of the Sales Agreement, any portion of the $100,000,000 included in the sales agreement prospectus supplement that remains unsold will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no common shares are sold under the Sales Agreement, the full $100,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED AUGUST 12, 2025</div>

PROSPECTUS

<div align='center'>$100,000,000

Common Shares

Warrants

Units</div>

We may from time to time offer to sell any combination of common shares, warrants to purchase common shares and units comprised of one or more of the other securities described in this prospectus in one or more offerings. The aggregate offering price of all securities sold under this prospectus will not exceed $100,000,000.

This prospectus provides a general description of the securities that we may offer. Each time we sell securities, we will provide the specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you invest in any securities. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus